|
|
|
Size
|
publishing SR protocols in a peer reviewed journal
|
Craig Lockwood |
Tue, 2 Oct 2018 07:12:46 +0000 |
98 lines |
Re: publishing SR protocols in a peer reviewed journal
|
Frances Gardner |
Tue, 2 Oct 2018 08:03:22 +0000 |
203 lines |
Hiring Research Assistant--Center for Evidence-based Policy, Portland, Oregon
|
Valerie King |
Tue, 2 Oct 2018 18:54:40 +0000 |
500 lines |
Re: The 'Cost' of Open Access
|
Anoop B |
Wed, 3 Oct 2018 09:10:38 -0400 |
553 lines |
Sponsorship: how it shapes the agendas of researchers.
|
Juan Gérvas |
Wed, 3 Oct 2018 20:00:02 +0200 |
77 lines |
FREE Special issue of Evidence & Policy
|
Heather Gibson |
Thu, 4 Oct 2018 14:30:08 +0000 |
449 lines |
Editorial bias
|
David Nunan |
Fri, 5 Oct 2018 10:48:38 +0000 |
161 lines |
David Healy blog: Cochrane: Collaboration or Cult?
|
Tom Jefferson |
Fri, 5 Oct 2018 17:58:31 +0200 |
59 lines |
Re: David Healy blog: Cochrane: Collaboration or Cult?
|
Juan Gérvas |
Fri, 5 Oct 2018 18:18:55 +0200 |
128 lines |
Re: David Healy blog: Cochrane: Collaboration or Cult?
|
Juan Gérvas |
Fri, 5 Oct 2018 22:05:06 +0200 |
186 lines |
Re: David Healy blog: Cochrane: Collaboration or Cult?
|
Juan Gérvas |
Sat, 6 Oct 2018 13:10:48 +0200 |
224 lines |
Re: Editorial bias
|
Amy Price |
Sat, 6 Oct 2018 15:44:23 +0000 |
341 lines |
Re: Editorial bias
|
Amy Price |
Sat, 6 Oct 2018 20:46:19 +0000 |
253 lines |
Systematic search strategy for systematic review
|
Juan Gérvas |
Sun, 7 Oct 2018 11:39:42 +0200 |
49 lines |
Re: David Healy blog: Cochrane: Collaboration or Cult?
|
Juan Gérvas |
Sun, 7 Oct 2018 12:41:26 +0200 |
310 lines |
Australian Clinical Trials Alliance (ACTA) Summit: 29-30 November 2018
|
Miranda Cumpston |
Mon, 8 Oct 2018 17:37:33 +1100 |
153 lines |
Jos Verbeek, Coordinating Editor. Cochrane Crisis
|
Juan Gérvas |
Mon, 8 Oct 2018 10:49:17 +0200 |
77 lines |
Registrations open for short courses in SDM and Health Literacy plus Evidence for decision making
|
Lyndal Trevena |
Tue, 9 Oct 2018 01:04:52 +0000 |
325 lines |
BestEvidence - A free mobile app to find high quality evidence quickly
|
Burls, Amanda |
Tue, 9 Oct 2018 13:16:46 +0000 |
203 lines |
Re: BestEvidence - A free mobile app to find high quality evidence quickly
|
Ben Goldacre |
Wed, 10 Oct 2018 20:11:56 +0100 |
226 lines |
PowerPoint
|
Juan Gérvas |
Wed, 10 Oct 2018 23:44:25 +0200 |
40 lines |
Re: BestEvidence - A free mobile app to find high quality evidence quickly
|
Carla Hagstrom |
Thu, 11 Oct 2018 01:18:15 +0000 |
271 lines |
Methods Q: Rapid versus systematic reviews - assessing which generates most benefit/least harm
|
Jon Brassey |
Thu, 11 Oct 2018 06:35:59 +0100 |
81 lines |
Re: Methods Q: Rapid versus systematic reviews - assessing which generates most benefit/least harm
|
Claire Beecroft |
Thu, 11 Oct 2018 13:13:02 +0100 |
261 lines |
Re: Transvaginal mesh: no EBM
|
Juan Gérvas |
Thu, 11 Oct 2018 16:49:03 +0200 |
556 lines |
Re: Jos Verbeek, Coordinating Editor. Cochrane Crisis
|
Juan Gérvas |
Thu, 11 Oct 2018 19:06:29 +0200 |
132 lines |
Re: BestEvidence - A free mobile app to find high quality evidence quickly
|
Burls, Amanda |
Thu, 11 Oct 2018 20:56:45 +0000 |
542 lines |
Re: Methods Q: Rapid versus systematic reviews - assessing which generates most benefit/least harm
|
McCormack, James |
Thu, 11 Oct 2018 21:35:28 +0000 |
127 lines |
Re: BestEvidence - A free mobile app to find high quality evidence quickly
|
Ben Goldacre |
Thu, 11 Oct 2018 22:48:56 +0100 |
658 lines |
Re: BestEvidence - A free mobile app to find high quality evidence quickly
|
Barry Diner |
Thu, 11 Oct 2018 17:12:20 -0500 |
555 lines |
JBI-accredited Systematic Review Short Course (January 7th-11th 2019)
|
Catrin Evans |
Fri, 12 Oct 2018 09:13:45 +0000 |
535 lines |
Short courses at the University of Bristol Medical School
|
Short Course Co-ordinator |
Fri, 12 Oct 2018 12:42:41 +0100 |
68 lines |
London School of Hygiene & Tropical Medicine: Research Fellow post for statistician / epidemiologist
|
Jan vanderMeulen |
Fri, 12 Oct 2018 15:24:39 +0000 |
442 lines |
EQUATOR Publication School 8-9 November 2018, Oxford, UK
|
Caroline Struthers |
Fri, 12 Oct 2018 16:51:52 +0000 |
298 lines |
Re: BestEvidence - A free mobile app to find high quality evidence quickly
|
Burls, Amanda |
Sun, 14 Oct 2018 14:53:18 +0000 |
680 lines |
Treatment burden in clinical guidelines
|
Juan Gérvas |
Sun, 14 Oct 2018 20:55:16 +0200 |
63 lines |
Guide to Health Economics Analysis and Research (GEAR) Website
|
Alia luz |
Mon, 15 Oct 2018 05:40:47 +0100 |
38 lines |
Qualitative Research Methods Courses at the University of Oxford - Winter 2018 to Spring 2019
|
HERG Qualitative Research Courses |
Mon, 15 Oct 2018 10:53:10 +0000 |
445 lines |
Let study subjetivity
|
Juan Gérvas |
Mon, 15 Oct 2018 15:52:17 +0200 |
74 lines |
Re: Let study subjetivity
|
David Richard Leslie Cawthorpe |
Mon, 15 Oct 2018 14:23:51 +0000 |
86 lines |
Re: Let study subjetivity
|
Shaughnessy, Allen |
Mon, 15 Oct 2018 11:18:45 -0400 |
175 lines |
Re: Let study subjetivity
|
Anoop B |
Tue, 16 Oct 2018 08:20:56 -0400 |
216 lines |
Re: Treatment burden in clinical guidelines
|
Per Olav Vandvik |
Wed, 17 Oct 2018 14:02:48 +0200 |
178 lines |
Washing machine of conflict of interest. HPV vaccine
|
Juan Gérvas |
Wed, 17 Oct 2018 14:30:42 +0200 |
47 lines |
Re: Washing machine of conflict of interest. HPV vaccine
|
Bewley, Susan |
Wed, 17 Oct 2018 13:12:35 +0000 |
154 lines |
Re: Washing machine of conflict of interest. HPV vaccine
|
Kev Hopayian |
Wed, 17 Oct 2018 15:45:22 +0100 |
217 lines |
open/free software for meta regression
|
Craig Lockwood |
Thu, 18 Oct 2018 05:16:13 +0000 |
73 lines |
Do boring speakers really talk for longer? YES.
|
Juan Gérvas |
Thu, 18 Oct 2018 12:01:22 +0200 |
48 lines |
Re: open/free software for meta regression
|
Susan Salmond |
Thu, 18 Oct 2018 17:44:07 +0000 |
229 lines |
Re: open/free software for meta regression
|
Craig Lockwood |
Thu, 18 Oct 2018 21:45:13 +0000 |
144 lines |
Re: open/free software for meta regression
|
Lahart, Ian |
Fri, 19 Oct 2018 07:34:00 +0000 |
90 lines |
Leeds Mixed Methods Systematic Reviews and Literature Searching for Mixed Methods Reviews Courses. Jan 2019. Early Bird booking now
|
Judy Wright |
Fri, 19 Oct 2018 11:35:04 +0000 |
283 lines |
HPV vaccines and deaths. Wrong attribution. Cochrane Review. Cochrane Crisis.
|
Juan Gérvas |
Sat, 20 Oct 2018 23:20:34 +0200 |
167 lines |
Re: Treatment burden in clinical guidelines
|
Cristian Baicus |
Sun, 21 Oct 2018 13:25:11 +0300 |
142 lines |
How could a median survival be longer than the median follow-up?
|
Cristian Baicus |
Mon, 22 Oct 2018 12:59:45 +0300 |
75 lines |
LDL and mortality (and use of statins)
|
Juan Gérvas |
Mon, 22 Oct 2018 16:41:34 +0200 |
81 lines |
Re: LDL and mortality (and use of statins)
|
Anoop B |
Mon, 22 Oct 2018 11:09:20 -0400 |
129 lines |
Re: LDL and mortality (and use of statins)
|
McCormack, James |
Mon, 22 Oct 2018 15:41:37 +0000 |
182 lines |
Re: [MARKETING] LDL and mortality (and use of statins)
|
Johnson, Ian (MAN-CMH) |
Mon, 22 Oct 2018 16:39:13 +0000 |
236 lines |
Re: LDL and mortality (and use of statins)
|
Bill Cayley, Jr |
Mon, 22 Oct 2018 16:43:57 +0000 |
358 lines |
Re: LDL and mortality (and use of statins)
|
Anoop B |
Mon, 22 Oct 2018 13:17:43 -0400 |
479 lines |
Re: LDL and mortality (and use of statins)
|
Kev Hopayian |
Mon, 22 Oct 2018 18:24:01 +0100 |
132 lines |
Re: LDL and mortality (and use of statins)
|
Juan Gérvas |
Mon, 22 Oct 2018 23:53:35 +0200 |
203 lines |
Re: LDL and mortality (and use of statins)
|
McCormack, James |
Mon, 22 Oct 2018 22:14:30 +0000 |
267 lines |
Senior Research Officer- Diabetes Living Evidence
|
Tari Turner |
Tue, 23 Oct 2018 10:19:47 +1100 |
262 lines |
Re: Senior Research Officer- Diabetes Living Evidence
|
Tari Turner |
Tue, 23 Oct 2018 11:59:34 +1100 |
335 lines |
Re: LDL and mortality (and use of statins)
|
David Nunan |
Tue, 23 Oct 2018 09:42:58 +0000 |
399 lines |
Re: LDL and mortality (and use of statins)
|
Juan Gérvas |
Tue, 23 Oct 2018 21:15:42 +0200 |
698 lines |
Re: LDL and mortality (and use of statins)
|
Juan Gérvas |
Tue, 23 Oct 2018 21:32:42 +0200 |
486 lines |
Re: LDL and mortality (and use of statins)
|
Bill Cayley, Jr |
Tue, 23 Oct 2018 20:32:54 +0000 |
584 lines |
Re: LDL and mortality (and use of statins)
|
McCormack, James |
Tue, 23 Oct 2018 20:34:46 +0000 |
486 lines |
Re: LDL and mortality (and use of statins)
|
Jordan Panayotov |
Tue, 23 Oct 2018 23:10:08 +0000 |
796 lines |
EBM Live - July 2019
|
Ruth Davis |
Wed, 24 Oct 2018 13:02:38 +0000 |
395 lines |
Authoritarianism at Cochrane
|
Tom Jefferson |
Thu, 25 Oct 2018 16:34:57 +0200 |
90 lines |
New Course - Advanced Qualitative Research Methods
|
University of Oxford CPD Centre |
Thu, 25 Oct 2018 16:49:04 +0100 |
141 lines |
Re: BMJ News reporting 14% increased risk of ACEI associated lung cancer
|
Vivek Podder |
Thu, 25 Oct 2018 21:56:18 +0600 |
56 lines |
Invitation to stand for election to the Governing Board [Cochrane]
|
Manitoba Hunter |
Fri, 26 Oct 2018 00:26:04 +0000 |
68 lines |
Re: Authoritarianism at Cochrane
|
Vasiliy Vlassov |
Sat, 27 Oct 2018 12:01:51 +0300 |
55 lines |
Re: Authoritarianism at Cochrane
|
Tom Jefferson |
Sat, 27 Oct 2018 14:34:42 +0200 |
144 lines |
Re: Authoritarianism at Cochrane
|
Vasiliy Vlassov |
Sat, 27 Oct 2018 20:43:32 +0300 |
102 lines |
Re: Authoritarianism at Cochrane
|
Andrzej Glowinski |
Sat, 27 Oct 2018 19:35:09 +0100 |
116 lines |
Re: Authoritarianism at Cochrane
|
Federico Barbani USL |
Sun, 28 Oct 2018 22:38:25 +0100 |
311 lines |
Re: Authoritarianism at Cochrane
|
Kumara Mendis |
Mon, 29 Oct 2018 06:30:06 +0530 |
490 lines |
Re: Authoritarianism at Cochrane
|
Kumara Mendis |
Mon, 29 Oct 2018 06:33:17 +0530 |
403 lines |
Baloxavir as oseltamivir, no EBM
|
Juan Gérvas |
Mon, 29 Oct 2018 19:55:16 +0100 |
117 lines |
Re: Authoritarianism at Cochrane
|
Juan Gérvas |
Tue, 30 Oct 2018 11:36:25 +0100 |
526 lines |
Re: LDL and mortality (and use of statins)
|
Juan Gérvas |
Tue, 30 Oct 2018 20:25:43 +0100 |
886 lines |
Re: LDL and mortality (and use of statins)
|
McCormack, James |
Tue, 30 Oct 2018 19:57:32 +0000 |
742 lines |
Re: LDL and mortality (and use of statins)
|
Cristian Baicus |
Tue, 30 Oct 2018 22:31:53 +0200 |
156 lines |
Re: LDL and mortality (and use of statins)
|
Juan Gérvas |
Tue, 30 Oct 2018 21:59:30 +0100 |
1106 lines |
Re: LDL and mortality (and use of statins)
|
McCormack, James |
Wed, 31 Oct 2018 03:17:51 +0000 |
1001 lines |
Re: LDL and mortality (and use of statins)
|
Juan Gérvas |
Wed, 31 Oct 2018 10:54:57 +0100 |
1415 lines |
Re: LDL and mortality (and use of statins)
|
Owen Dempsey |
Wed, 31 Oct 2018 11:16:07 +0000 |
1668 lines |
Re: LDL and mortality (and use of statins)
|
Owen Dempsey |
Wed, 31 Oct 2018 14:18:13 +0000 |
1834 lines |
Re: LDL and mortality (and use of statins)
|
McCormack, James |
Wed, 31 Oct 2018 15:45:11 +0000 |
1548 lines |
Re: LDL and mortality (and use of statins)
|
Evelyn Cornelissen |
Wed, 31 Oct 2018 10:00:21 -0700 |
2075 lines |
Re: LDL and mortality (and use of statins)
|
McCormack, James |
Wed, 31 Oct 2018 17:02:58 +0000 |
2282 lines |
Re: LDL and mortality (and use of statins)
|
Rod Jackson |
Wed, 31 Oct 2018 21:32:49 +0000 |
1077 lines |
Re: LDL and mortality (and use of statins)
|
Mohammed T. Ansari |
Wed, 31 Oct 2018 18:15:28 -0400 |
1916 lines |